Virtual Library
Start Your Search
Y.S. Park
Author of
-
+
P2.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 234)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.04-036 - The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas (ID 2210)
09:30 - 09:30 | Author(s): Y.S. Park
- Abstract
Background:
The prognostic role of epidermal growth factor receptor (EGFR) mutations in patients with lung adenocarcinomas remains controversial and the association between EGFR mutations and stage at the time of the initial diagnosis is debatable. Here we evaluated the association of EGFR mutations with initial stage in lung adenocarcinomas.
Methods:
From June 2011 to December 2014, 1004 consecutive patients who were diagnosed with lung adenocarcinomas and tested for EGFR mutations were retrospectively analyzed. As screening detects lung cancer at early stage, screening was incorporated as a confounder in multivariable analysis.
Results:
Among 1004 patients with lung adenocarcinomas, EGFR mutations were detected in 49.2% (494 of 1004). In multivariable analysis, EGFR mutations were significantly associated with early stage (stage I to II) at diagnosis (OR, 0.65; 95% CI, 0.49 to 0.87; P = 0.003). When adjusted for age, sex, smoking status, and screening, adjusted proportion of EGFR mutations significantly decreased according to stage. Adjusted proportion of EGFR was 57.6% (95% CI, 51.7% to 63.3%) in stage I, 47.9% (95% CI, 36.9% to 59.0%) in stage II, 47.5% (95% CI, 39.6% to 55.5%) in stage III, and 43.4% (95% CI, 38.3% to 48.6%) in stage IV (P = 0.0082).
Conclusion:
The presence of EGFR mutations is significantly associated with early stage at initial diagnosis in lung adenocarcinomas after adjusting for age, sex, smoking status, and screening. This finding implies that EGFR mutations may play a role as a positive prognostic marker.
-
+
P3.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 235)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.04-117 - Clinical Characteristics and Survival Outcome of Non-Small Cell Lung Cancer According to Age (ID 2522)
09:30 - 09:30 | Author(s): Y.S. Park
- Abstract
Background:
Clinical characteristics of non-small cell lung cancer (NSCLC) in young age are different from those of older patients. The aim of this study was to compare the survival according to age with adjustment for major confounding factors including major drugable mutations (EGFR and ALK).
Methods:
From June 2011 to December 2014, 1860 consecutive newly diagnosed NSCLC patients were recruited. Among them, we divided 4 groups according to age; group I (age<40), group II (40≤age<60), group III (60≤age<80), and group IV (age>80). We compared survival using 3 different Cox proportional hazard model; unadjusted model, model 1 (adjusted for sex, smoking, BMI, ECOG performance status, histology of adenocarcinoma, initial stage), and model 2 (model 1 + drugable mutations).
Results:
Among 1860 patients, mean age was 66.1 years old, and 64.7% was male. Never smokers were 38.0% and adenocarcinoma observed in 62.0%. EGFR and ALK mutations were detected in 40.3% and 5.1%, respectively. The numbers of patients were 29 in group I, 436 in group II, 1276 in group III, and 119 in group IV. In Cox proportional hazard model, survival differences between age groups were significant in unadjusted model and model 1. But after adjustment for drugable mutations (model 2), the survival difference was not significant.
Conclusion:
Survival on NSCLC in young age was not different from that older patients, after adjustment for sex, smoking, BMI, ECOG performance status, histology of adenocarcinoma, initial stage and major drugable mutations (EGFR and ALK).
